Bortezomib

Product Name:Bortezomib
Synonyms:Bortezomib for Injection;3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid;Boronic acid, B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]bu;MG-341 PS-341;BortezoMib Base;BortezoMib-D8;bortezoMib(other);MLM341
CAS:179324-69-7
MF:C19H25BN4O4
MW:384.24
EINECS:605-854-3
Product Categories:ProteasomeInhibitors;Apis;Boron Derivatives;Inhibitors;Intermediates & Fine Chemicals;Inhibitor;Final material;API;peptides;Pharmaceuticals;Pepetides
Type:Antineoplastic Agents, API
Appearance:White or off-white powder
Purity:99%
Melting point:122-124°C
Density:1.214
Grade Standard:Medicine Grade
Package:100G;1KG;5KG;10KG;25KG;50KG;100KG. For small quantity: Bag Commercial quantity: fiber drum Or as per customers required
Description:Bortezomib, a modified dipeptidyl boronic acid, is a therapeutic proteasome inhibitors used for the treatment of cancers. It is indicated for the treatment of relapsed multiple myeloma and mantle cell lymphoma. It is capable of inhibiting the mammalian 26S proteasome, which is important in regulating the intracellular concentration of specific proteins to maintain homeostasis within cells. The disruption of 26S proteasome function disrupts normal cellular homeostasis, leading to cytotoxic effect on various kinds of cancer cells.
Uses:Bortezomib is the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.